Login to Your Account



NitroMed Cuts Back R&D To Ready For BiDil Sales Push

By Randall Osborne


Monday, April 3, 2006
With an extended-release version of its heart drug for black patients in the works, NitroMed Inc. is cutting about 30 positions in research and development and stepping up efforts to out-license or partner its preclinical nitric-oxide enhancing program. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription